Milestone Pharmaceuticals Inc. (MIST) reported its fourth-quarter and full-year 2025 results, revealing a wider net loss of $17.4 million for Q4 and a total loss of $63.1 million for the year. Despite these losses, the company achieved $1.54 million in revenue through a milestone payment related to the FDA approval of its lead product, CARDAMYST (Etripamil), which is now the first self-administered nasal spray for treating paroxysmal supraventricular tachycardia (PSVT).
The approval of CARDAMYST and its subsequent launch in U.S. retail pharmacies is a significant milestone for Milestone Pharma, as the company aims to penetrate the cardiology market with a dedicated sales team. The European Medicines Agency has accepted the marketing application for Etripamil, with a decision anticipated in the first half of 2027, potentially expanding the product’s market reach.
Investors should note MIST’s recent stock performance, which has seen a modest increase of 4.41% in after-hours trading, indicating market optimism surrounding the product launch and future revenue potential.
Source: nasdaq.com